Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health Companies (NYSE/TSX: BHC) will present a business and strategic update during a fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022. CEO Joseph C. Papa expressed enthusiasm regarding the progress in unlocking company value, highlighting that preparations for the IPOs of Bausch + Lomb and Solta are nearly complete, pending market and regulatory conditions. The presentation will be available on their Investor Relations page.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that CEO Joseph C. Papa will speak at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 a.m. ET. A live webcast of the event will be available on the company's Investor Relations page. Bausch Health is committed to improving lives through a range of healthcare products, focusing on eye health, gastroenterology, and dermatology.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the publication of a post-hoc analysis in The Journal of Emergency Medicine supporting RELISTOR (methylnaltrexone bromide) injection for treating opioid-induced constipation in severely ill patients with insufficient laxative response. The study revealed a significant increase in rescue-free laxation rates: 61.4% within 4 hours compared to 16% for placebo. Notably, RELISTOR did not compromise opioid pain relief, although gastrointestinal side effects were reported. This reinforces RELISTOR's therapeutic value, particularly in emergency settings.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its dermatology product, JUBLIA^® (efinaconazole) Topical Solution, has received the American Podiatric Medical Association (APMA) Seal of Approval. This recognition signifies the product's safety and efficacy in treating onychomycosis, a common fungal infection affecting toenails. JUBLIA^® has been available since 2014 for adults and was approved for children in 2020. The APMA's endorsement comes after a rigorous scientific review process, enhancing JUBLIA's credibility in the market.

Bausch Health and Salix Pharmaceuticals launched digital initiatives for Constipation Awareness Month, focusing on opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C), and chronic idiopathic constipation (CIC). Their campaign aims to enhance patient education and awareness through platforms like TikTok and revamped websites, including UnderstandingOIC.com. Highlights include partnerships with healthcare influencers to discuss symptoms and treatment options, addressing the fact that 40-80% of chronic pain patients experience OIC.

Bausch + Lomb, part of Bausch Health (NYSE/TSX: BHC), announced that its exclusive recycling programs, ONE by ONE and Biotrue®, have successfully recycled over 41 million units (248,516 pounds) of used contact lens and eye care materials. The Biotrue® program is the first of its kind in the U.S., having collected more than 65,000 units since launch. These initiatives, in partnership with TerraCycle, promote sustainability by addressing waste that typically ends up in landfills. The company aims to expand these efforts to further reduce environmental impact.

Kroll Bond Rating Agency (KBRA) has released its Third-Quarter 2021 U.S. Bank Compendium, providing insights into the U.S. banking sector's performance and outlook for 2022. The report reviews 3Q21 results for U.S. banks under KBRA ratings, focusing on key credit metrics and ratios. Additionally, it highlights the top 10 banks with the lowest cost deposits and analyzes changes in return on assets and nonperforming asset ratios. The compendium also includes a detailed supplement of 187 rated bank debt issues. Amalgamated Financial Corp. (NASDAQ: AMAL) holds a BBB rating with a Stable Outlook.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its gastroenterology business, Salix Pharmaceuticals, will present new data on rifaximin at The Liver Meeting™ 2021, taking place virtually from Nov. 12-15, 2021. Two abstracts will be available to registered attendees, highlighting studies on rifaximin's role in reducing hospitalization and mortality in patients with hepatic encephalopathy, as well as its use in emergency department services for cirrhosis patients. XIFAXAN® (rifaximin) is indicated for reducing hepatic encephalopathy recurrence and treating IBS-D.